Physiological and Biochemical Differences between Diabetes Type 1 and Diabetes Type 2

dc.contributor.advisorFarlane, Jim
dc.contributor.authorAlmutairi, Majed
dc.date.accessioned2024-08-07T08:45:10Z
dc.date.available2024-08-07T08:45:10Z
dc.date.issued2017-10-20
dc.description.abstractThe expression "diabetes" is gotten from the ancient Greek word 'diabainen', which means ‘go through’, to show the too much passage of urine from the kidney. Until the 1600s it was not included, nonetheless, that Willis included the expression "mellitus" ('sweet') to recognize this condition from an unreasonable production of non-sweet urine (diabetes 'insipidus')(Poretsky, 2010). Just about 200 years after the fact (1776), Dobson showed that sweet taste of urine wasbecause of an abundance of sugar in blood and urine. Another 100 more years were needed to demonstrate the pathogenesis of diabetes mellitus. In 1889, von Mering and Minkowski showed that pancreatectomised dogs created manifestations of diabetes, thus first time connecting diabetes surprisingly to a particular organ. In 1910, Sharpey-Schafer recommended that diabetic peoples were inadequate in a substance created in the pancreatic islets (found in 1869 by Langerhans) and called it 'insulin'; in this manner, a connection between the pancreas, insulin and diabetes was begun to develop and thus modern period of diabetes study started. It was just in 1921, in any case, that a more exact picture developed: Banting, Macleod and Best demonstrated that diabetes in pancreatectomised dogs could be turned around after the intravenous organization of the "islet" extracted from typical canine ancreata. Then, Best, Banting and Collip refined this substance from bovinepancreata, and the first patient was effectively treated in 1922, bringing about a decrease in blood glucose as well as glycosuria. In 1926, MacLean recommended a difference between 'hepatic glycosuria' and 'genuine diabetes'. After ten years, Himsworth, compressing his past research, recognized 'insulin-dependent' and 'insulin-independent' diabetes mellitus, with the last more treacherous condition portrayed by less serious hyperglycaemia. In the 1950s, a solid estimation of circling insulin with a radioimmunoassay system permitted a reasonable difference between 'insulin-dependent' and 'insulin-independent' diabetes mellitus, and the worldview of two pathophysiologically distinct disordersturned out to be increasingly clear in the folowing years (Zaccardi, Webb, Yates, & Davies, 2016).
dc.format.extent26
dc.identifier.urihttps://hdl.handle.net/20.500.14154/72797
dc.language.isoen
dc.publisherUniversity of New England
dc.subjectexpression "diabetes"
dc.subjectType I diabetes mellitus.
dc.subjectType II diabetes mellitus.
dc.subjectprimary types of diabetes mellitus
dc.subjectFisetin
dc.subjecttetrahydroxy flavones
dc.subjectpathogenesis of diabetes mellitus.
dc.subjectinsulin-independent
dc.subjectblood glucose
dc.subjectpancreatectomised dogs
dc.subjectglycosuria
dc.subjectBeta cells
dc.subjectexpression "mellitus"
dc.subjectDiabetes
dc.subjectpathophysiologic
dc.subjectActivation of auto-immunity
dc.subjectCell secretory capacity
dc.subjectT2DM
dc.subjectNEFA
dc.subjecthigh-fat diet (HFD)
dc.subjectfollicle stimulating hormone (FSH)
dc.subjectrandomized controlled trials (RCTs)
dc.subjectglucose-bringing down
dc.subjectGlucose-lowering drugs
dc.subjectDPP-4 inhibitors (DPP-4i)
dc.subjectsulfonylureas (SU)
dc.subjectGLP-1 receptor agonists (GLP-1RA)
dc.subjectSGLT2 inhibitors (SGLT2i)
dc.subjectTZDs and insulin
dc.subjectalpha 2-macroglobulinlevels
dc.subjectInsulin decreases
dc.subjectHLA
dc.subjectangiosperms
dc.subjectneuroprotective
dc.subjectantiviral
dc.subjectanti-inflammatory activities
dc.subjectbenzo-γ-pyrone moiety
dc.subjecthydroxylated phenolic
dc.subjectpolymerization
dc.subjectHypoglycemic efficacy of Fisetin
dc.subjectFisetin Actions on Glucose Metabolism
dc.subjectNADH-NADþ
dc.subjectpyruvate
dc.subjectreducing glycogen
dc.subjectdelaying glycogenolytic
dc.subjecthormones
dc.subjectFisetin as anti-glycation agent
dc.subjectglyoxalase 1 (Glo-1)
dc.subjectglutathione (GSH)
dc.subjectmethylglyoxal (MG)
dc.subjectglycation viamethylglyoxal (MG)
dc.subjectSTZ
dc.subjectenlarged fibrosis
dc.subjectplasmacytic
dc.subjectFisetin reduces HG-tempted vascular inflammation
dc.subjecthuman umbilical vein endothelial cells (HUVECs)
dc.subjectnuclear factor (NF)-jB
dc.subjectCAMs
dc.subjectMNCV
dc.subjectCOX-2
dc.subjectNrf2
dc.subjectPEPCK
dc.subjectmRNA
dc.titlePhysiological and Biochemical Differences between Diabetes Type 1 and Diabetes Type 2
dc.title.alternativeThe potential Therapeutic Effects of Fisetin in Diabetes.
dc.typeThesis
sdl.degree.departmentBiomedical Science
sdl.degree.disciplineBiomedical Science
sdl.degree.grantorNew England
sdl.degree.nameMaster of Scientific Studies

Files

Collections

Copyright owned by the Saudi Digital Library (SDL) © 2024